Sep 19 2009
Resolvyx Pharmaceuticals, Inc., the leading Resolvin therapeutics company, today announced that the U.S. Patent and Trademark Office has granted a patent (U.S. Patent 7,582,785) covering composition of matter for RX-10045, the first Resolvin therapeutic to enter clinical trials. RX-10045 has been formulated as a topical eye drop that was recently evaluated in a Phase 2 clinical study showing positive results for the treatment of patients with chronic dry eye syndrome.
"Just last month, we reported positive results from a 232-patient Phase II trial in which RX-10045 improved both signs and symptoms of chronic dry eye,” stated Greg Weinhoff, M.D., Executive Chairman of Resolvyx. “We are very pleased to have the first US patent covering this class of compounds that has the potential to be an important therapy for chronic dry eye syndrome and other ophthalmic diseases.”
In addition to this patent, Resolvyx has an issued patent in Europe and a pending patent application in the US for RX-10001, an orally available Resolvin therapeutic currently in Phase 1 testing with potential to treat inflammatory bowel disease, asthma and other inflammatory diseases. The company has over 80 issued or pending patent applications in the U.S. and worldwide covering the resolvin platform of compounds.
http://www.resolvyx.com./
Obesity crisis in the U.S. expected to worsen by 2050